|
Cell lines database
p53 database
p53 mutations in cell lines
The hanbook of p53 mutation in cell lines
Cell lines with a controversial p53 status
The NCI 60 panel
Bladder cancer cell lines
Brain cancer cell lines
Breast cancer cell lines
Cervical carcinoma
Colorectal cancer cell lines
Esophageal cancer cell lines
Gastric cancer cell lines
Head and Neck cancer cell lines
Leukemia / Lymphoma cell lines
NSCLC cancer cell lines
Ovarian cancer cell lines
Pancreatic cancer cell lines
Sarcoma cell lines
SCLC cancer cell lines
Melanoma cell lines
Hepatocellular carcinoma
References
|
THE NCI-60 PANEL
Cell lines with an inconclusive p53 status are shown in red.
more information can be found here: Berglind et al., in press: download the manuscript
Cell line |
ATCC number |
DNA |
Protein |
ref |
consensus |
comment |
LYMPHOMA LEUKEMIA |
CCRF-CEM |
CCL-119 |
|
R248Q |
1018 |
R175H+R248Q |
Two mutations in separate alleles |
c.524G>A, c.743G>A |
R175H+R248Q |
3 |
c.524G>A, c.743G>A |
R175H+R248Q |
2249 |
HL-60 |
CCL-240 |
|
R248L |
1018 |
p53 null |
|
null |
p.M1_*394del |
3000 |
null |
p.M1_*394del |
2249 |
K-562 |
CCL-243 |
c.406_407insC |
p.Q136fs*13 |
269 |
p.Q136fs*13 |
p53 RNA and protein are undetectable in this cell line |
c.406_407insC |
p.Q136fs*13 |
2249 |
MOLT-4 |
CRL-1582 |
wt |
|
3 |
Inconclusive |
The status of MOLT-4 is highly heterogeneous in the literature. The report of a wt status could be due to the fact that only exons 5 to 8 (residues 126-306) were screened in several publications |
wt |
|
1018 |
c.331C>G |
L111V |
2242 |
c.743G>A |
R248Q |
27 |
c.916C>T |
R306X |
2249 |
RPMI-8226 |
CCL-155 |
|
R285L |
1018 |
E285K |
This mutant is temperature-sensitive |
c.853G>A |
E285K |
2249 |
c.853G>A |
E285K |
98 |
SR |
CRL-2262 |
wt |
|
1018 |
wt |
|
wt |
|
2249 |
NSCLC |
A549 |
CCL-185 |
wt |
|
1018 |
wt |
|
wt |
|
16 |
wt |
|
2249 |
EKVX |
|
del187-224 (exon 6) |
|
1018 |
Inconclusive |
Possible splicing defect. See below for more information |
c.609_610GG>TT |
p.V203_E204>V |
2249 |
HOP-62 |
|
|
Ins 212-225 |
1018 |
|
See below for more explanation |
c.673-2A>G (splice junction) |
p.? |
2249 |
HOP-92 |
|
|
p.R175L |
1018 |
R175L |
|
c.524G>T |
p.R175L |
2249 |
NCI-H226 |
CRL-5826 |
|
P309A |
1018 |
Inconclusive |
|
c.473G>T |
R158L |
92 |
|
wt |
2249 |
NCI-H23 |
CRL-5800 |
c.738G>C |
R246I |
17 |
R246I |
|
|
R246I |
1018 |
c.738G>C |
R246I |
2249 |
NCI-H322M |
|
c.743G>T |
R248L |
92 |
R248L |
|
|
R248L |
1018 |
c.743G>T |
R248L |
2249 |
NCI-H460 |
HTB-177 |
wt |
|
1018 |
wt |
|
wt |
|
2249 |
NCI-H522 |
CRL-5810 |
|
191delG |
1018 |
p.P191fs*57 |
|
c.572_572delC |
p.P191fs*57 |
2249 |
c.572_572delC |
p.P191fs*58 |
92 |
COLON |
COLO-205 |
CCL-222 |
|
G266E |
1018 |
Inconclusive |
|
c.308_333>TA |
p.Y103_L111>L |
492 |
c.308_333>TA |
103del27 |
2249 |
HCC-2998 |
|
|
R213X |
1018 |
R213X |
|
c.637C>T |
R213X |
2249 |
HCT-116 |
CCL-247 |
wt |
|
1018 |
wt |
|
wt |
|
2249 |
HCT-15 |
CCL-225 |
c.722C>T, c.1101-2A>C (splice junction) |
p.S241F, p.? |
2249 |
Inconclusive |
|
|
P153A |
1018 |
c.722C>T |
S241F |
2251 |
HT-29 |
HTB-38 |
c.818G>A |
R273H |
492 |
R273H |
|
c.818G>A |
R273H |
2249 |
KM12 |
|
|
H179R |
1018 |
Inconclusive |
|
c.215delG |
p.R72fs*51 |
2249 |
SW620 |
CCL-227 |
c.818G>A, c.925C>T |
R273H, P309S |
9 |
R273H + P309S |
SW480 and SW620 are derived from the same individual with a similar p53 alteration. The P309S mutation is not always reported |
|
R273H |
1018 |
c.818G>A, c.925C>T |
R273H, P309S |
2249 |
CENTRAL NERVOUS SYSTEN |
SF268 |
|
c.818G>A |
R273H |
664 |
R273H |
|
|
R273H |
1018 |
c.818G>A |
R273H |
2249 |
SF295 |
|
|
p.R248Q |
1018 |
R248Q |
|
c.743G>A |
p.R248Q |
2249 |
SF539 |
|
wt |
|
1018 |
Inconclusive |
|
c.1024delC |
p.R342fs*3 |
2249 |
SNB75 |
|
|
E258K |
1018 |
E258K |
|
c.772G>A |
E258K |
2249 |
U251/SNB19 |
|
c.818G>A |
R273H |
632 |
R273H |
|
|
R273H |
1018 |
c.818G>A |
R273H |
2249 |
MELANOMA |
LOXIMV1 |
|
wt |
|
1018 |
wt |
|
wt |
|
2249 |
Malme-3M |
HTB-64 |
wt |
|
1018 |
wt |
|
wt |
|
2249 |
M14 |
|
|
G266E |
1018 |
G266E |
|
c.797G>A |
G266E |
2249 |
SK-MEL-2 |
HTB-68 |
|
G245S |
1018 |
G245S |
|
c.733G>A |
G245S |
2249 |
SK-MEL-28 |
HTB-72 |
c.434_435TG>GT |
L145R |
2249 |
L145R |
|
c.434T>G |
L145R |
1570 |
|
C145V |
1018 |
SK-MEL-5 |
HTB-70 |
wt |
|
1018 |
wt |
|
wt |
|
2249 |
UACC-257 |
|
wt |
|
1018 |
wt |
|
wt |
|
2249 |
UACC-62 |
|
wt |
|
1018 |
wt |
|
|
|
2249 |
MDA-MB-435 |
|
|
G266E |
1018 |
G266E |
This cell line was originally reported as a breast carcinoma cell line but recent SNP analysis indicates that it is similar to the M14 melanoma cell line |
c.797G>A |
G266E |
2029 |
c.797G>A |
G266E |
2249 |
MDA-N |
|
|
G266E |
1018 |
G266E |
This cell line was originally reported as a breast carcinoma cell line but recent SNP analysis indicates that it is similar to the M14 melanoma cell line. It is a derivative of MDA-MB-435 tranfected with a plasmid expressing erbB2 |
OVARY |
IGROV1 |
|
wt |
|
1018 |
Inconclusive |
|
wt |
|
606 |
c.377A>G |
Y126C |
2249 |
OVCAR-3 |
HTB-161 |
c.743G>A |
R248Q |
144 |
R248Q |
|
|
R248Q |
1018 |
c.743G>A |
R248Q |
2249 |
OVCAR-4 |
|
wt |
|
1018 |
Inconclusive |
|
c.388C>G |
L130V |
2249 |
OVCAR-5 |
|
|
ins224 |
1018 |
Inconclusive |
|
wt |
|
2249 |
OVCAR-8 |
|
c.376-1G>A |
|
2249 |
Splicing defect |
See below for more explanation |
|
del 126-132 |
1018 |
NCI/ADR-RES |
|
c.376-1G>A |
|
2249 |
Splicing defect |
Originally named MCF-7/AdrR cells, later re-designated NCI/ADR-RES. Was recently found to be identical to OVCAR-8 |
|
del 126-132 |
1018 |
|
126del21 |
983 |
SK-OV-3 |
HTB-77 |
|
H179R |
1018 |
Inconclusive |
p53 RNA and protein are undetectable in this cell line: see below for more explanation |
c.267delC |
p.S90fs*33 |
2249 |
RENAL |
786-0 |
CRL-1932 |
|
P278A |
1018 |
Inconclusive |
|
c.832C>G, c.560-2A>G (splice junction) |
p.P278A, p.? |
2249 |
A498 |
HTB-44 |
wt |
|
1018 |
wt |
|
wt |
|
2249 |
ACHN |
CRL-1611 |
wt |
|
1018 |
wt |
|
wt |
|
2249 |
CAKI-1 |
HTB-46 |
wt |
|
1018 |
wt |
|
wt |
|
2249 |
RXF393 |
|
|
R175H |
1018 |
R175H |
|
c.524G>A |
R175H |
2249 |
SN12C |
|
|
E336X |
1018 |
E336X |
|
c.1006G>T |
E336X |
2249 |
TK10 |
|
|
L264R |
1018 |
L264R |
|
c.791T>G |
L264R |
2249 |
U031 |
|
wt |
|
1018 |
wt |
|
wt |
|
2249 |
PROSTATE |
DU-145 |
HTB-81 |
|
P223L |
1018 |
P223L + V274F |
See below for more explanation |
c.820G>T |
V274F |
2249 |
c.668C>T + c.820G>T |
P223L + V274F |
3001 |
c.668C>T + c.820G>T |
P223L + V274F |
59 |
PC-3 |
CRL-1435 |
c.414delC |
p.K139fs*31 |
2249 |
p53 RNA and protein are undetectable in this cell line |
|
|
138del |
1018 |
c.414delC |
138del |
59 |
BREAST |
BT-549 |
HTB-122 |
c.747G>C |
R249S |
24 |
R249S |
|
|
R249S |
1018 |
c.747G>C |
R249S |
2249 |
Hs 578T |
HTB-126 |
c.469G>T |
V157F |
76 |
V157F |
|
c.469G>T |
V157F |
2249 |
|
D157E |
1018 |
MCF7 |
HTB-22 |
wt |
|
1018 |
wt |
|
wt |
|
249 |
MDA-MB-231 |
HTB-26 |
c.839G>A |
R280K |
24 |
R280K |
|
|
R280K |
1018 |
T47D |
HTB-133 |
c.580C>T |
L194F |
9 |
L194F |
|
c.580C>T |
L194F |
1018 |
In EKVX, the deletion of codon 187 to 224 detected on RNA-based analysis (ref 1018) corresponds exactly to the deletion of the entire exon 6, a strong argument for a splicing defect. Genomic analysis did not reveal a splicing defect but a tandem mutation at codons 203 and 204 in exon 6 (ref 2049). If the two cell lines analysed were really EKVX, this result suggests that a mutation at either codon 203 and/or 204 could affect p53 gene splicing
In OVCAR-8, the 126-132 deletion detected by the RNA-based assay (ref 1018) concerns the first six residues of exon 5. Genomic analysis (ref 2049) described a mutation in the acceptor site of exon 5 and a splicing defect leading to a shift of the normal donor site of exon 5 that skips 18 nucleotides (6 aa residues) in exon 5. Examination of the DNA sequence at codon 132 reveals an AG dinucleotide sequence preceded by a pyrimidine tract similar to those found in the splice donor sequence. The same situation is observed for NCI/ADR- RES that has been recently shown to be an ovarian carcinoma cell line originating from the same patient as OVCAR-8.
In HOP-62, RNA-based analysis (ref 1018) detected an insertion between codon 212-225 but no information about the insertion sequence was available. Codon 225 is at the boundary of exon 6 and intron 6 suggesting a splicing defect, as analysis at the genomic level (ref 2049) confirms the presence of a splice mutation in the acceptor signal of exon 6
In the majority of publications, the p53 status of the SK-OV-3 cell line is stated as “p53 null”. In fact, close examination of the original manuscript shows that the p53 gene in SK-OV-3 is not deleted and did not sustain any gross rearrangement but neither p53 RNA or protein are found. In these publications, no p53 mutations were found but the recent analysis performed at the Sanger Institute detected a deletion of a single nucleotide at position 267 (codon 90) (Ikediobi et al., 2006). It is therefore possible that nonsense-mediated mRNA decay (NMD) eliminates p53 aberrant mRNA. NMD has been observed in the human leukaemia cell line K562 where p53 is also inactivated via a 1 base pair insertion at nucleotide 136
|
|